Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Inve...View More
Vyome Therapeutics Inc. has announced a $22 million financing for the phase IIb trial of its lead mo...View More
Vyome Therapeutics' lead product, which targets the drug-resistant acne market, received approval of...View More
Proceeds to finance phase 2b clinical trial for a drug with novel mechanism of action against modera...View More
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.